Comparing the current results to its competitors, Acurx Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.15 %, recorded in the same quarter.
Acurx Pharmaceuticals inc , slower than the average decrease reported by the company's competitors of -83.4 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -83.4 %
Acurx Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is characterized by rapid technological advancements and intense competition. Its competitors include major pharmaceutical, specialty pharmaceutical, and biopharmaceutical companies, as well as academic institutions, government agencies, and private and public research organizations. These competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, marketing, recruitment of qualified personnel, and acquisition of complementary technologies. Additionally, small or early-stage companies, particularly those collaborating with larger firms, may also present significant competition. The company's commercial opportunities may be affected if competitors develop products that are safer, more effective, or have fewer or less severe side effects.
Publicly Traded Peers of Acurx Pharmaceuticals inc
Viatris Inc Share Performance
+2.11%
30 Days
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Sources:
Acurx Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Acurx Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
